Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels

dc.contributor.authorKim, Jaeho
dc.contributor.authorChoe, Yeong Sim
dc.contributor.authorPark, Yuhyun
dc.contributor.authorKim, Yeshin
dc.contributor.authorKim, Jun Pyo
dc.contributor.authorJang, Hyemin
dc.contributor.authorKim, Hee Jin
dc.contributor.authorNa, Duk L.
dc.contributor.authorCho, Soo-Jin
dc.contributor.authorMoon, Seung Hwan
dc.contributor.authorSeo, Sang Won
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2023-11-15T14:56:01Z
dc.date.available2023-11-15T14:56:01Z
dc.date.issued2023-03-02
dc.description.abstractBackground: Although the standardized uptake value ratio (SUVR) method is objective and simple, cut-off optimization using global SUVR values may not reflect focal increased uptake in the cerebrum. The present study investigated clinical and neuroimaging characteristics according to focally increased β-amyloid (Aβ) uptake and global Aβ status. Methods: We recruited 968 participants with cognitive continuum. All participants underwent neuropsychological tests and 498 18F-florbetaben (FBB) amyloid positron emission tomography (PET) and 470 18F-flutemetamol (FMM) PET. Each PET scan was assessed in 10 regions (left and right frontal, lateral temporal, parietal, cingulate, and striatum) with focal-quantitative SUVR-based cutoff values for each region by using an iterative outlier approach. Results: A total of 62 (6.4%) subjects showed increased focal Aβ uptake with subthreshold global Aβ status [global (-) and focal (+) Aβ group, G(-)F(+) group]. The G(-)F(+) group showed worse performance in memory impairment (p < 0.001), global cognition (p = 0.009), greater hippocampal atrophy (p = 0.045), compared to those in the G(-)F(-). Participants with widespread Aβ involvement in the whole region [G(+)] showed worse neuropsychological (p < 0.001) and neuroimaging features (p < 0.001) than those with focal Aβ involvement G(-)F(+). Conclusion: Our findings suggest that individuals show distinctive clinical outcomes according to focally increased Aβ uptake and global Aβ status. Thus, researchers and clinicians should pay more attention to focal increased Aβ uptake in addition to global Aβ status.
dc.eprint.versionFinal published version
dc.identifier.citationKim J, Choe YS, Park Y, et al. Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels. Front Aging Neurosci. 2023;15:1124445. Published 2023 Mar 2. doi:10.3389/fnagi.2023.1124445
dc.identifier.urihttps://hdl.handle.net/1805/37057
dc.language.isoen_US
dc.publisherFrontiers Media
dc.relation.isversionof10.3389/fnagi.2023.1124445
dc.relation.journalFrontiers in Aging Neuroscience
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectAmyloid PET imaging
dc.subjectFlorbetaben
dc.subjectFlutemetamol
dc.subjectAlzheimer’s disease
dc.subjectFocal amyloid uptake
dc.titleClinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
fnagi-15-1124445.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: